Do We Have the Courage? Pregnancy, Policy, and the Price Surgeons Pay
Editor's Choice: Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialt...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Gynecologic Oncology
This new series of monthly podcasts will feature information on a wealth of emerging topics in the field of Gynecological Oncology. Each month one of our Editor's will have an in-depth conve...
Episodes
20 of 73 episodes
FIGO 2023 Upstaging: Overtreatment or Overdue Precision?
Editor's Choice: FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer Editorial: A path to precision in endometri...
ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know
Editor's Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update Editorial: The evolving la...
Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer
Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olapa...
Cologuard-like test for identification of endometrial cancer through vaginal sampling
Editor's Choice: Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding Editorial:...
PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic o...
Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery
Editor's Choice: Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer Editorial: Same-day...
Recognizing and Managing ADC-Associated Pulmonary Toxicities
Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement Check out mo...
In good SHAPE
Editor's Choice: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cerv...
ctDNA-Guided PARPi Therapy in Ovarian Cancer
Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize...
Beyond treatment: The who, why, when, where and what of cancer follow up
Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches Editorial: Who is...
Ovarian Cancer After Breast Cancer in Women with BRCA Variants
Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant Editorial: Does a diagnosis of breast...
Making a difference: Molecules, mechanisms and more
Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurr...
Navigating Surgical Complexity After Ovarian Cancer Neoadjuvant Chemotherapy
Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer Hosted by:...
Cervical Cancer Care in Focus: Consensus on Quality, Equity, and Radiation Therapy
Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, A...
Beyond Anesthesia: Self-Hypnosis in ERAS Programs
Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomiz...
Carcinosarcoma Wars: A New Hope for TROP-2 Therapeutic Targeting
Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcoma Editorial: The search for new therapeutic options for...
To divert or not to divert: that is the question
Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective s...
A randomized clinical trial of metformin in endometrial cancer
Editor’s choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therap...
Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer
Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometr...